Citations

Showing 10 of 108094 citations.

Current Practice Review in the Management of Acute Respiratory Distress Syndrome
Chudow, Melissa, Condeni, Melanie S. , Heavner, Mojdeh S. , Nei, Andrea M. , Smith, Melanie , Chudow, Melissa B , Heavner, Mojdeh S , Dhar, Sandipan , Bissell, Brittany D.

Mayo Clinic

Journal of Pharmacy Practice | June 21, 2022 | Volume: 36 | Issue: 6 | Pages: 1454-1471

10.1177/08971900221108713 | PMID 35728076 Get It

Acute respiratory distress syndrome (ARDS) presents as an acute inflammatory lung injury characterized by refractory hypoxemia and non-cardiac pulmonary edema. An estimated 10% of patients in the intensive care unit and 25% of those who are mechanically ventilated are diagnosed with ARDS. Increased awareness is warranted as mortality rates remain high and delays in diagnosing ARDS are common. The COVID-19 pandemic highlights the importance of understanding ARDS management. Treatment of ARDS can be challenging due to the complexity of the disease state and conflicting existing evidence. Therefore, it is imperative that pharmacists understand both pharmacologic and non-pharmacologic treatment strategies to optimize patient care. This narrative review provides a critical evaluation of current literature describing management practices for ARDS. A review of treatment modalities and supportive care strategies will be presented.
Recent Use of Non–Vitamin K Antagonist Oral Anticoagulants and Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase
Brown, Caitlin S. , Webb, Andrew , Rech, Megan A.

Mayo Clinic

JAMA | June 21, 2022 | Volume: 327 | Issue: 23 | Pages: 2354

10.1001/jama.2022.6350 | PMID 35727284 Get It

A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)
Fischer, Luca , Patten, Piers , Smith, Sonali M. , Ubieto, Ana Jiménez , Davis, Keith L. , Nagar, Saurabh , Bollu, Vamsi , Jousseaume, Etienne, Ramos, Roberto , Link, Brian K. , Link, Brian K , Patten, Piers E M , Salles, Gilles , Schuster, Stephen J. , Kuruvilla, John , Tresckow, Bastian von , Zhang, Jie , Wang, Yucai

Mayo Clinic

HemaSphere | June 21, 2022 | Volume: 6 | Issue: 7 | Pages: e745

10.1097/hs9.0000000000000745 | PMID 35813099 Get It

This study (ReCORD-FL) sought to construct a historical control cohort to augment single-arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 centers across North America and Europe was conducted. Adults with grade 1–3A FL were required to be r/r after ≥2 therapy lines including an anti-CD20 and an alkylator. After first becoming r/r, patients were required to initiate ≥1 additional therapy line, which defined the study index date. Endpoints were observed from start of each therapy line (including index line) until death, last follow-up, or December 31, 2020. Endpoints were complete response (CR) rate, overall response rate (ORR), time to next treatment or death (TNT-D), event-free survival (EFS), and overall survival (OS). One hundred eighty-seven patients were identified. Most patients’ (80.2%) index therapy occurred in third line (3L) (range, 3L–6L). Median follow-up from FL diagnosis was 9 years (range, 1–21 years). CR and ORR to the index therapy were 39.0% and 70.6%, respectively. Median (95% confidence interval) EFS from index was 14.6 (11.0-18.0) months; median OS from index was 10.6 years. Outcomes worsened across successive treatment lines and for patients who were double refractory (r/r to both an anti-CD20 monoclonal antibody and an alkylator) or POD24 (progressed ≤24 months after front-line anti-CD20) at index. Findings demonstrate the unmet need of FL patients with multiply relapsed, double refractory, or POD24 disease. Based on robustness of the historical data collected and comparability with a previous study (SCHOLAR-5), ReCORD-FL presents a valuable source of control data for comparative studies in r/r FL.
IL-4 prevents adenosine-mediated immunoregulation by inhibiting CD39 expression
Cao, Wenqiang , Mu, Yunmei, Okuyama, Hirohisa , Li, Lingjie , Qiu, Jingtao , Weyand, Cornelia M. , Goronzy, Jörg J. , Goronzy, Jorg , Cao, Wenqiang , Fang, Fengqin

Mayo Clinic

JCI Insight | June 21, 2022 | Volume: 7 | Issue: 12 | Pages: No page available

10.1172/jci.insight.157509 | PMID 35730568 Get It

The ectonucleotidase CD39 functions as a checkpoint in purinergic signaling on effector T cells. By depleting eATP and initiating the generation of adenosine, it impairs memory cell development and contributes to T cell exhaustion, thereby causing defective tumor immunity and deficient T cell responses in older adults who have increased CD39 expression. Tuning enzymatic activity of CD39 and targeting the transcriptional regulation of ENTPD1 can be used to modulate purinergic signaling. Here, we describe that STAT6 phosphorylation downstream of IL-4 signaling represses CD39 expression on activated T cells by inducing a transcription factor network including GATA3, GFI1, and YY1. GATA3 suppresses ENTPD1 transcription through prevention of RUNX3 recruitment to the ENTPD1 promoter. Conversely, pharmacological STAT6 inhibition decreases T cell effector functions via increased CD39 expression, resulting in the defective signaling of P2X receptors by ATP and stimulation of A2A receptors by adenosine. Our studies suggest that inhibiting the STAT6 pathway to increase CD39 expression has the potential to treat autoimmune disease while stimulation of the pathway could improve T cell immunity.
Clinical and electrophysiological findings in C9ORF72 ALS
Sista, Sri Raghav, Shelly, Shahar , Oskarsson, Björn , Rubin, Devon I., Martinez‐Thompson, Jennifer M. , Parra‐Cantu, Carolina , Staff, Nathan P. , Laughlin, Ruple S. , Sista, Sri Raghav S , Oskarsson, Björn , Staff, Nathan P , Shahar, Shelly

Mayo Clinic

Muscle & Nerve | June 21, 2022 | Volume: 66 | Issue: 3 | Pages: 270-275

10.1002/mus.27665 | PMID 35727129 Get It

AbstractIntroduction/AimsAmyotrophic lateral sclerosis (ALS) is a progressive, fatal, neurodegenerative disorder of motor neurons in which the cause is mostly unknown. Early identification of genetic ALS cases, of which C9ORF72 (C9ALS) is the most frequent, can have important implications for evaluation, prognosis, and therapeutics. Here, we aimed to characterize the clinical and electrophysiological hallmarks of C9ALS and investigate differences from C9ORF72 negative ALS (non‐C9ALS).MethodsWe retrospectively reviewed clinical and electrodiagnostic (EDX) data for all genetically confirmed C9ALS cases seen between 1/1/2012 and 10/1/2020 who met Gold Coast criteria and compared them 1:1 with non‐C9ALS patients within the same time frame.ResultsA total of 99 C9ALS and 99 non‐C9ALS cases were identified. Compared to non‐C9ALS, C9ALS demonstrated higher prevalence in women, lesser racial variability, stronger family history of ALS, and higher frequency of upper motor neuron signs. EDX testing of C9ALS showed higher median sensory nerve and lower fibular compound muscle action potential amplitudes.DiscussionAlthough the differences between C9ALS and non‐C9ALS reached statistical significance in certain nerve conduction parameters, they were not sufficient to discriminate between groups on a case‐by‐case basis. Genetic testing is required to identify C9ALS patients.
Natural Pattern of Cognitive Aging
Novotný, Jan , Vassilaki, Maria , Krell‐Roesch, Janina , Geda, Yonas E. , Stokin, Gorazd B. , Krell-Roesch, Janina, Geda, Yonas E , Novotny, Jan S , Stokin, Gorazd , González‐Rivas, Juan P.

Mayo Clinic

Journal of Alzheimer's Disease | June 21, 2022 | Volume: 88 | Issue: 3 | Pages: 1147-1155

10.3233/jad-220312 | PMID 35754277 Get It

Background: Considering the world’s rapidly increasing life expectancy, with people working and maintaining active lifestyles longer than ever before, addressing the effects of aging on cognition is of utmost importance. A greater understanding of cognitive aging may also be critical in distinguishing natural cognitive aging from pre-clinical stages of Alzheimer’s disease and related cognitive disorders. Objective: To systematically examine the association between aging and cognitive performance in a cognitively and otherwise healthy probability population-based sample using a computer-based method. Methods: This cross-sectional study enrolled 673 cognitively and otherwise healthy participants aged 25–89 years (mean age 52.3±14.2 years, 52.5% of whom were female) from the Kardiovize study cohort. Mild cognitive impairment and dementia cases were excluded, followed by measurement of cognitive performance with the computer-administered Cogstate Brief Battery. We used ANCOVA and Modified Signed-Likelihood Ratio tests to examine patterns of cognition across age groups. Results: We found a gradual decrease in cognitive performance across the lifespan, which required two decades to demonstrate significant changes. In contrast to attention and learning, psychomotor speed and working memory showed the most significant age-related decrease and variability in performance. The established pattern of cognitive aging was not altered by sex or education. Conclusion: These findings corroborate, validate, and extend the current understanding of natural cognitive aging and pinpoint specific cognitive domains with the most extensive age-related interindividual differences. This will contribute to the development of strategies to preserve cognition with aging and may also serve to improve early diagnostics of cognitive disorders using computer-based methods.
Effect of caloric intake and macronutrient composition on intestinal cholesterol absorption and bile acids in patients with obesity
Hashem, Anas , Cifuentes, Lizeth , Ricardo-Silgado, Maria Laura , Gonzalez‐Izundegui, Daniel, Campos, Alejandro , Mcrae, Alison, Franks, Shawna, Burton, Duane, Petterson, Xuan-Mai, Camilleri, Michael , Hashem, Anas Mohamad , Calderon, Gerardo, Gonzalez-Izundegui, Daniel, Hurtado, Maria Daniela , Lanza, Ian R , Camilleri, M , Acosta, Andres , Campos, Alejandro , Calderon-Lopez, Gerardo , Hurtado, Maria D. , Lanza, Ian R. , Acosta, Andrés

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | June 21, 2022 | Volume: 323 | Issue: 3 | Pages: G157-G164

10.1152/ajpgi.00108.2022 | PMID 35727128 Get It

We show how switching from a regular diet to an HCHF increases cholesterol absorption in patients with normal weight and obesity. The decrease in cholesterol absorption from an HCHF to an LCLF, on the other hand, was only seen in normal-weight controls, underlining the importance of body weight in this regulation. In addition, changes in caloric and fat content had an immediate and direct effect on hepatic bile acid production.
Online clinical tool to estimate risk of bronchopulmonary dysplasia in extremely preterm infants
Greenberg, Rachel G. , McDonald, Scott A. , Tanaka, David , Jensen, Erik A. , Meurs, Krisa P. Van , Eichenwald, Eric C. , Duncan, Andrea, Walsh, Michele C. , Das, Abhik , Cotten, C. Michael , Brumbaugh, Jane E. , Das, Abhik , Laughon, Matthew Maxwell , Duncan, Andrea F.

Mayo Clinic

Archives of Disease in Childhood - Fetal and Neonatal Edition | June 21, 2022 | Volume: 107 | Issue: 6 | Pages: 638-643

10.1136/archdischild-2021-323573 | PMID 35728925 Get It

Objective Develop an online estimator that accurately predicts bronchopulmonary dysplasia (BPD) severity or death using readily-available demographic and clinical data. Design Retrospective analysis of data entered into a prospective registry. Setting Infants cared for at centres of the United States Neonatal Research Network between 2011 and 2017. Patients Infants 501–1250 g birth weight and 23 0/7–28 6/7 weeks’ gestation. Interventions None. Main outcome measures Separate multinomial regression models for postnatal days 1, 3, 7, 14 and 28 were developed to estimate the individual probabilities of death or BPD severity (no BPD, grade 1 BPD, grade 2 BPD, grade 3 BPD) defined according to the mode of respiratory support administered at 36 weeks’ postmenstrual age. Results Among 9181 included infants, birth weight was most predictive of death or BPD severity on postnatal day 1, while mode of respiratory support was the most predictive factor on days 3, 7, 14 and 28. The predictive accuracy of the models increased at each time period from postnatal day 1 (C-statistic: 0.674) to postnatal day 28 (C-statistic 0.741). We used these results to develop a web-based model that provides predicted estimates for BPD by postnatal day. Conclusion The probability of BPD or death in extremely preterm infants can be estimated with reasonable accuracy using a limited amount of readily available clinical information. This tool may aid clinical prognostication, future research, and center-specific quality improvement surrounding BPD prevention. Trial registration number NCT00063063
A Crown of Gold
Kwon, Joshua , Koop, Andree , Francis, Dawn L., Kwon, Joshua Y , Francis, Dawn

Mayo Clinic

ACG Case Reports Journal | June 21, 2022 | Volume: 9 | Issue: 6 | Pages: e00807

10.14309/crj.0000000000000807 | PMID 35734287 Get It